Kadimastem Ltd - Asset Resilience Ratio

Latest as of September 2016: 16.66%

Kadimastem Ltd (KDST) has an Asset Resilience Ratio of 16.66% as of September 2016. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KDST working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

ILA1.20 Million

≈ $3.22K USD Cash + Short-term Investments

Total Assets

ILA7.20 Million

≈ $19.31K USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2015)

This chart shows how Kadimastem Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Kadimastem Ltd balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Kadimastem Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Kadimastem Ltd total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA1.20 Million	16.66%
Total Liquid Assets	ILA1.20 Million	16.66%

Asset Resilience Insights

Good Liquidity Position: Kadimastem Ltd maintains a healthy 16.66% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Kadimastem Ltd Industry Peers by Asset Resilience Ratio

Compare Kadimastem Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Kadimastem Ltd (2013–2015)

The table below shows the annual Asset Resilience Ratio data for Kadimastem Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2015-12-31	31.57%	ILA2.50 Million ≈ $6.70K	ILA7.92 Million ≈ $21.23K	-24.87pp
2014-12-31	56.45%	ILA6.79 Million ≈ $18.20K	ILA12.02 Million ≈ $32.24K	+0.90pp
2013-12-31	55.55%	ILA6.89 Million ≈ $18.48K	ILA12.41 Million ≈ $33.27K	--

pp = percentage points

About Kadimastem Ltd

TA:KDST Israel Biotechnology

Market Cap

$22.18 Million

ILA8.27 Billion ILA

Market Cap Rank

#24864 Global

#355 in Israel

Share Price

ILA2794.00

Change (1 day)

-1.13%

52-Week Range

ILA2794.00 - ILA3680.00

All Time High

ILA78228.15